Antibodies targeting talaromyces marneffei mp1p protein and methods of use thereof
US-2024199726-A1 · Jun 20, 2024 · US
Antibodies against infectious diseases
US11485776B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11485776-B2 |
| Application number | US-202016937447-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 23, 2020 |
| Priority date | Apr 1, 2015 |
| Publication date | Nov 1, 2022 |
| Grant date | Nov 1, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides anti-CaENO1 antibodies and humanized antibodies as effective diagnostic agent or therapeutic treatment against infections caused by Candida spp. (preferably Candida. albicans, Candida tropicalis), fluconazole resistance Candida spp., Streptococcus, or Staphylococcus.
First claim
Opening claim text (preview).
What is claimed is: 1. A polypeptide consisting of an epitope, consisting of 283 LYEQLISEYP 292 (SEQ ID NO:1), 278 PQLADLYEQL 287 (SEQ ID NO:2), 240 KGKVGIAMDV 249 (SEQ ID NO:3) or 278 PQLADLYEQLISEYP 292 (SEQ ID NO:4). 2. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier, excipient or adjuvant. 3. The pharmaceutical composition of claim 2 , which is a vaccine. 4. The pharmaceutical composition of claim 2 , which further comprises one or more additional anti- Candida , anti- Streptococcus or anti- Staphylococcus drugs. 5. The pharmaceutical composition of claim 4 , wherein the additional anti- Candida drug is fluconazole, itraconazole, posaconazole, echinocandins, voriconazole, lipid formulations of amphotericin B, Ketoconazole, clotrimazole, econazole, ciclopirox, or nystatin. 6. The pharmaceutical composition of claim 5 , wherein the echinocandin is caspofungin, micafungin, anidulafungin or ciclopirox.
Assignees
Inventors
Classifications
comprising antibodies · CPC title
- C07K16/14Primary
against material from fungi, algea or lichens · CPC title
against material from animals or humans · CPC title
Antimycotics · CPC title
Single chain antibody (scFv) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11485776B2 cover?
- The invention provides anti-CaENO1 antibodies and humanized antibodies as effective diagnostic agent or therapeutic treatment against infections caused by Candida spp. (preferably Candida. albicans, Candida tropicalis), fluconazole resistance Candida spp., Streptococcus, or Staphylococcus.
- Who is the assignee on this patent?
- Univ Taipei Medical
- What technology area does this patent fall under?
- Primary CPC classification C07K16/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).